What Happened?

We are developing an innovative` entirely new class of medicines called ``RNAi therapeutics``to treat rare genetic` cardio metabolic` acute hepatic infectious and central nervous system (CNS) diseases.
Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNA interference (RNAi)` and a bold vision that this discovery could be used to silence disease-causing genes upstream of today`s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall` we believe that patients shouldn`t have to wait for hope.
Alnylam is turning scientific possibility into reality - in August of 2018` the U.S. FDA and European Union`s EMA approval of our first product ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. Our robust RNAi discovery platform and deep pipeline of investigational medicines includes three programs in late-stage clinical development and multiple programs in early-stage clinical development.
We are a global and diverse company of more than 850 people. We pride ourself on fostering a fun` inclusive and dynamic work environment where employees can recognize their fullest potential. That`s why we`ve been named a Boston Globe Top Place to Work three years in a row!
We are based in Cambridge` U.S.` with offices in Zug` Switzerland` and Maidenhead` UK` and operations and employees across the U.S. and throughout Europe and Asia.